



**Aarti Drugs Limited**

Manufacturers of : Bulk Drugs & Chemicals

**Corporate Office :** Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)  
Fax.: 022-2407 3462 / 2407 0144  
Email: admin@aartidrugs.com  
website: www.aartidrugs.com  
CIN No.:L37060MH1984PLC055433

**Ref: ADL/SE/2020-21**

**July 27, 2020**

To,  
Listing/ Compliance Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001  
BSE ID: AARTIDRUGS  
**BSE CODE – 524348**

To,  
Listing/ Compliance Department  
**National Stock Exchange of India  
Limited,**  
“Exchange Plaza”, Bandra - Kurla  
Complex, Bandra (E), Mumbai – 400051  
**NSE SYMBOL: AARTIDRUGS**

Dear Sir/Madam,

**Sub: Press Release for June 2020**

Please find attached herewith press release on the Financial Results for the quarter ended June 30, 2020.

Kindly take the same on record.

Thanking you,

Yours faithfully,

**FOR AARTI DRUGS LIMITED**

RUSHIKESH DEOLE

**COMPANY SECRETARY & COMPLIANCE OFFICER**

ICSI M.No.: A54527



**Aarti Drugs Limited**

Manufacturers of : Bulk Drugs & Chemicals

**Corporate Office :** Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)  
Fax.: 022-2407 3462 / 2407 0144  
Email: admin@aartidrugs.com  
website: www.aartidrugs.com  
CIN No.:L37060MH1984PLC055433

### **Press release for June'2020**

In the June'2020 quarter, the Company recorded consolidated quarterly revenue of Rs.544.67 Crores with year-on-year increase of 34.34%. API segment contributed approximately 85% and formulation around 15% of the total consolidated revenues. Domestic sales of the API segment grew by approximately 28.19% and exports by 29.13%. Around 50% of the Y-o-Y growth in the API segment was due to volume growth. Formulation segment revenues grew by around 89.49% on a year-on-year basis on the account of high export growth.

Consolidated EBITDA for the quarter ended June'2020 is Rs.135.23 Crores, up by 146.89% and consolidated profit after tax for the quarter ended June 2020 is Rs.85.45 Crores, up by 280.63% on a year-on-year basis. Consolidated EBITDA margin improved to 24.83%. Despite challenges faced during COVID19 lockdown, the Company was able to maintain good operational efficiency which along with good realization in selling prices led to increased gross margins. Debt/Equity ratio of the Company reduced further down to 0.55 as of June'2020 on a consolidated basis.

Company has already scaled up its anti-diabetic and anti-inflammatory capacity and it will give impetus to revenue growth in FY20-21. This would be further supported by good growth in formulation exports. Additional CAPEX is planned for introducing new products in anti-diabetic category towards the end of FY20-21. As the lockdown is easing out project work should pick up pace in coming quarters. Company also positively looks forward towards the recently announced PLI scheme by the government. The company is also planning to do further backward integration of its products to reduce Imports dependency.

**FOR AARTI DRUGS LIMITED**

ADHISH P. PATIL

**CHIEF FINANCIAL OFFICER**